ReviewDrugs2007
Atorvastatin: a safety and tolerability profile.
Review in Drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03696940 (Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants.Advances in therapy · 2024Trial
- Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial.Journal of neurology · 2012Trial
- Comparison of pharmacokinetics of a fixed-dose combination of atorvastatin/ezetimibe 5 mg/10 mg versus separate tablets in healthy subjects.Translational and clinical pharmacology · 2025Article
- Quality assessment of different brands of atorvastatin tablets available in Riyadh, Saudi Arabia.BMC pharmacology & toxicology · 2022Article
- Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide.Pharmacology research & perspectives · 2022Article
- Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model.Pediatric blood & cancer · 2019Article
- Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils.Journal of clinical and diagnostic research : JCDR · 2017Article
- Atorvastatin-induced prolonged cholestasis with bile duct damage.Clinical drug investigation · 2010Article
- Current awareness: pharmacoepidemiology and drug safety.Pharmacoepidemiology and drug safety · 2008Article
- Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.PharmacoEconomics · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive data are available on the safety of atorvastatin from randomised clinical trials, postmarketing analyses and reports to regulatory agencies. Atorvastatin is generally well tolerated across the range of therapeutic dosages, with the exception of a slightly higher rate of liver enzyme elevations with atorvastatin 80 mg/day which does not appear to confer an increased risk of clinically important adverse events. Unlike simvastatin, atorvastatin is associated with a low incidence of muscular toxicity. It is not associated with neurological, cognitive or renal adverse effects and does not require dosage adjustment in patients with renal dysfunction, due to its favourable pharmacokinetic profile, which is unique among the statins. In patients aged > or =65 years, atorvastatin is well tolerated with no dose-dependent increase in adverse events up to the maximum daily dosage of 80 mg/day. Thus, atorvastatin is a safe and well tolerated statin for use in a wide range of patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.